TNF Pharmaceuticals Inc. (TNFA) Company Profile - Business Overview, Management Team & Corporate Information - Stocknear

TNF Pharmaceuticals Inc.

NASDAQ: TNFA · Real-Time Price · USD
3.52
-0.28 (-7.37%)
At close: Sep 03, 2025, 3:21 PM

Company Description

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company.

It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms.

Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.

The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.

The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy.

The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs.

TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024.

The company was founded in 2014 and is headquartered in Baltimore, Maryland.

TNF Pharmaceuticals Inc.
TNF Pharmaceuticals Inc. logo
Country United States
IPO Date Jan 23, 2014
Industry Biotechnology
Sector Healthcare
Employees 2
CEO Mitchell Glass

Contact Details

Address:
855 N. Wolfe Street
New York City, New York
United States
Website https://tnfpharma.com

Stock Details

Ticker Symbol TNFA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code n/a
CUSIP Number 62856X300
ISIN Number US62856X3008
Employer ID -
SIC Code n/a

Key Executives

Name Position
Ian Rhodes CPA Interim Chief Financial Officer
Dr. Mitchell Glass M.D. President, Chief Medical Officer & Director
Robert Schatz Investor Relations Officer

Latest SEC Filings

No SEC filings available.